News

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the fiscal year ended December 31, 2024, and highlighted clinical updates and business progress.

04/03/2025

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, and LaunXP International Co., Ltd., an affiliate of LaunXP Biomedical Co., Ltd. (TWO: 6876) (“LaunXP”), announced today that the parties have entered into an agreement for the development and commercialization in Asia (excluding mainland China, Hong Kong and Macau) (the “LaunXP Territory”) of vebreltinib, Apollomics' proprietary c-Met inhibitor, in combination with an EGFR inhibitor (“EGFRi”) for the treatment of NSCLC. The EGFRi class of targeted kinase inhibitors is currently a foundational targeted therapy for the treatment of NSCLC and other tumor types.

03/31/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Apollomics, Inc. (APLM) a buy, sell, or hold?

Apollomics, Inc. (APLM) can sell. Click on Rating Page for detail.

What is Apollomics, Inc.'s stock price?

The price of Apollomics, Inc. (APLM) is 5.9597 and it was updated on 2025-07-09 13:00:20.

Is Apollomics, Inc. (APLM) overvalued or undervalued?

Currently Apollomics, Inc. (APLM) is in undervalued.

News

From:

To:

News
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today the results from its Phase 3 bridging trial of uproleselan in China in patients with relapsed or refractory acute myeloid leukemia. The trial did not demonstrate favorable benefit for uproleselan. Fri, Dec. 20, 2024
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that on December 10, 2024, it received a notification (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Rule 5550(a)(2) (the “Bid Price Requirement”), and Nasdaq has determined to continue the listing of the Company's Class A ordinary shares (“Class A Ordinary Shares”) on the Nasdaq Capital Market under the symbol “APLM.” Tue, Dec. 10, 2024
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced Company management will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference taking place on September 9-11, 2024 virtually and in person at the Lotte New York Palace Hotel in New York, NY. Wed, Sep. 04, 2024
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress FOSTER CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2024 ended June 30, 2024, and highlighted updates for its pipeline. Wed, Aug. 14, 2024
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial 43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with solid tumors harboring MET gene fusions 43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients with solid tumors harboring MET gene fusions Tue, Aug. 13, 2024

Transcripts

Transcipts Data
Apollomics, Inc. (APLM) on Q4 2023 Results - Earnings Call Transcript SA Transcripts Thu, Mar. 28, 2024

SEC Filings

SEC Filings
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 04/03/2025
Apollomics, Inc. (APLM) - 20-F SEC Filings 04/03/2025
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 03/31/2025
Apollomics, Inc. (APLM) - SCHEDULE 13G/A SEC Filings 01/10/2025
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 12/20/2024
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 12/10/2024
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 11/14/2024
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 11/01/2024
Apollomics, Inc. (APLM) - SC 13D/A SEC Filings 08/15/2024
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 08/14/2024
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 08/01/2024
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 07/16/2024
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 07/03/2024
Apollomics, Inc. (APLM) - EFFECT SEC Filings 05/30/2024
Apollomics, Inc. (APLM) - SC 13G/A SEC Filings 05/30/2024
Apollomics, Inc. (APLM) - 424B3 SEC Filings 05/29/2024
Apollomics, Inc. (APLM) - CORRESP SEC Filings 05/28/2024
Apollomics, Inc. (APLM) - UPLOAD SEC Filings 05/24/2024
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 05/24/2024
Apollomics, Inc. (APLM) - 424B5 SEC Filings 05/24/2024
Apollomics, Inc. (APLM) - SC 13D/A SEC Filings 05/22/2024
Apollomics, Inc. (APLM) - SC 13G SEC Filings 05/20/2024
Apollomics, Inc. (APLM) - F-3 SEC Filings 05/20/2024
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 05/08/2024
Apollomics, Inc. (APLM) - EFFECT SEC Filings 04/25/2024
Apollomics, Inc. (APLM) - EFFECT SEC Filings 04/25/2024
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 04/25/2024
Apollomics, Inc. (APLM) - 424B3 SEC Filings 04/24/2024
Apollomics, Inc. (APLM) - CORRESP SEC Filings 04/22/2024
Apollomics, Inc. (APLM) - F-3/A SEC Filings 04/19/2024
Apollomics, Inc. (APLM) - CORRESP SEC Filings 04/19/2024
Apollomics, Inc. (APLM) - UPLOAD SEC Filings 04/16/2024
Apollomics, Inc. (APLM) - UPLOAD SEC Filings 04/12/2024
Apollomics, Inc. (APLM) - CORRESP SEC Filings 04/12/2024
Apollomics, Inc. (APLM) - F-3 SEC Filings 04/01/2024
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 03/28/2024
Apollomics, Inc. (APLM) - 20-F SEC Filings 03/28/2024
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 03/04/2024
Apollomics, Inc. (APLM) - 424B3 SEC Filings 03/04/2024
Apollomics, Inc. (APLM) - SC 13G SEC Filings 02/27/2024
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 01/19/2024
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 01/08/2024
Apollomics, Inc. (APLM) - SC 13D/A SEC Filings 11/29/2023
Apollomics, Inc. (APLM) - 144 SEC Filings 11/27/2023
Apollomics, Inc. (APLM) - SC 13D/A SEC Filings 11/20/2023
Apollomics, Inc. (APLM) - 424B3 SEC Filings 11/16/2023
Apollomics, Inc. (APLM) - 144 SEC Filings 11/16/2023
Apollomics, Inc. (APLM) - SC 13D/A SEC Filings 11/01/2023
Apollomics, Inc. (APLM) - 144 SEC Filings 10/30/2023
Apollomics, Inc. (APLM) - 424B3 SEC Filings 10/26/2023
Apollomics, Inc. (APLM) - 424B3 SEC Filings 10/25/2023
Apollomics, Inc. (APLM) - SC 13D SEC Filings 10/10/2023
Apollomics, Inc. (APLM) - 144 SEC Filings 10/05/2023
Apollomics, Inc. (APLM) - EFFECT SEC Filings 10/02/2023
Apollomics, Inc. (APLM) - SC 13D/A SEC Filings 10/02/2023
Apollomics, Inc. (APLM) - 424B3 SEC Filings 09/29/2023
Apollomics, Inc. (APLM) - POS AM SEC Filings 09/28/2023
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 09/28/2023
Apollomics, Inc. (APLM) - 424B3 SEC Filings 09/28/2023
Apollomics, Inc. (APLM) - EFFECT SEC Filings 07/25/2023
Apollomics, Inc. (APLM) - 424B3 SEC Filings 07/25/2023
Apollomics, Inc. (APLM) - CORRESP SEC Filings 07/20/2023
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 07/20/2023
Apollomics, Inc. (APLM) - F-1/A SEC Filings 07/07/2023
Apollomics, Inc. (APLM) - CORRESP SEC Filings 07/07/2023
Apollomics, Inc. (APLM) - UPLOAD SEC Filings 06/23/2023
Apollomics, Inc. (APLM) - S-8 SEC Filings 06/09/2023
Apollomics, Inc. (APLM) - F-1 SEC Filings 06/09/2023
Apollomics, Inc. (APLM) - 20-F SEC Filings 04/28/2023
Apollomics, Inc. (APLM) - SC 13D SEC Filings 04/12/2023
Apollomics, Inc. (APLM) - 20-F SEC Filings 03/31/2023
Apollomics, Inc. (APLM) - 6-K - Current report SEC Filings 03/30/2023
Apollomics, Inc. (APLM) - CERT SEC Filings 03/29/2023
Apollomics, Inc. (APLM) - 8-A12B SEC Filings 03/28/2023
Apollomics, Inc. (APLM) - SEC STAFF LETTER SEC Filings 03/06/2023
Apollomics, Inc. (APLM) - EFFECT SEC Filings 03/01/2023
Apollomics, Inc. (APLM) - 424B3 SEC Filings 02/28/2023
Apollomics, Inc. (APLM) - CORRESP SEC Filings 02/24/2023
Apollomics, Inc. (APLM) - F-4/A SEC Filings 02/21/2023
Apollomics, Inc. (APLM) - CORRESP SEC Filings 02/21/2023
Apollomics, Inc. (APLM) - UPLOAD SEC Filings 02/17/2023
Apollomics, Inc. (APLM) - F-4/A SEC Filings 02/10/2023
Apollomics, Inc. (APLM) - 425 SEC Filings 02/10/2023
Apollomics, Inc. (APLM) - F-4/A SEC Filings 12/23/2022
Apollomics, Inc. (APLM) - CORRESP SEC Filings 12/22/2022
Apollomics, Inc. (APLM) - UPLOAD SEC Filings 12/19/2022
Apollomics, Inc. (APLM) - F-4/A SEC Filings 12/15/2022
Apollomics, Inc. (APLM) - CORRESP SEC Filings 12/14/2022
Apollomics, Inc. (APLM) - UPLOAD SEC Filings 12/05/2022
Apollomics, Inc. (APLM) - SEC STAFF LETTER SEC Filings 12/02/2022
Apollomics, Inc. (APLM) - F-4 SEC Filings 11/22/2022
Apollomics, Inc. (APLM) - CORRESP SEC Filings 11/22/2022
Apollomics, Inc. (APLM) - 425 SEC Filings 11/15/2022
Apollomics, Inc. (APLM) - UPLOAD SEC Filings 10/26/2022
Apollomics, Inc. (APLM) - 425 SEC Filings 10/14/2022
Apollomics, Inc. (APLM) - 425 SEC Filings 10/07/2022
Apollomics, Inc. (APLM) - DRS SEC Filings 09/29/2022
Apollomics, Inc. (APLM) - 425 SEC Filings 09/15/2022
Apollomics, Inc. (APLM) - 425 SEC Filings 09/14/2022

Press Releases

StockPrice Release
Apollomics reports full year 2024 financial results and highlights clinical updates and business progress 04/03/2025
Apollomics and launxp announce development and commercialization agreement for vebreltinib 03/31/2025
Apollomics announces top-line results for phase 3 bridging trial of uproleselan in china in patients with relapsed or refractory acute myeloid leukemia 12/20/2024
Apollomics regains compliance with nasdaq's minimum bid price requirement 12/10/2024
Apollomics to present at the h.c. wainwright 26th annual global investment conference 09/04/2024
Apollomics reports first half 2024 financial results and highlights vebreltinib clinical progress 08/14/2024
Apollomics announces positive preliminary data of vebreltinib in patients with non-cns met fusion solid tumors from its phase 2 sparta trial 08/13/2024
Apollomics granted 180-day extension to regain compliance with nasdaq minimum bid price requirement 07/16/2024
Apollomics announces updated strategic focus and leadership team changes 07/03/2024
Apollomics announces approval of vebreltinib in china as a first-in-class treatment for gliomas with met fusion gene 04/25/2024
Apollomics presents vebreltinib data at the 2024 american association for cancer research (aacr) annual meeting 04/10/2024
Apollomics highlights clinical progress and reports full year 2023 financial results 03/28/2024
Apollomics appoints matthew plunkett, ph.d. as chief financial officer 03/04/2024
Apollomics to present at the oppenheimer 34th annual healthcare life sciences conference 02/07/2024
Apollomics receives nasdaq notification regarding minimum bid price deficiency 01/19/2024
Apollomics to participate in a fireside chat at the b. riley securities' 2024 virtual oncology conference 01/17/2024
Apollomics completes enrollment in phase 3 bridging study of uproleselan in chinese patients with relapsed/refractory acute myeloid leukemia 01/03/2024
Apollomics to present at the 2024 biotech showcase 01/02/2024
Apollomics to participate in a fireside chat at the h.c. wainwright 4th annual precision oncology virtual conference 11/29/2023
Apollomics announces presentation of vebreltinib data at the 2023 iaslc north america conference on lung cancer (naclc) 11/28/2023
Apollomics announces the first approval of vebreltinib for met exon 14 skip non-small cell lung cancer 11/16/2023
Apollomics announces two new cohorts in global phase 2 sparta study of vebreltinib in non-small cell lung cancer and other solid tumors with met dysregulation 10/31/2023
Apollomics announces report of activity of vebreltinib in glioblastoma multiforme (gbm) with ptprz-met fusion 10/26/2023
Apollomics announces efficacy of vebreltinib in nsclc patients with metex14 skipping mutation achieving an overall response rate (orr) of 75% 10/23/2023
Apollomics announces presentations of vebreltinib data at esmo 2023 10/16/2023
Apollomics reports first half 2023 financial results and provides corporate update 09/28/2023
Apollomics to present at the h.c. wainwright 25th annual global investment conference 09/06/2023

More Headlines

News
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today that it received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that it has granted the Company's request for a 180-day extension to regain compliance with the continued listing requirements for The Nasdaq Capital Market. As previously disclosed, Apollomics had received a notice from Nasdaq on January 16, 2024 that it is not in compliance with the Bid Price Requirement (as defined below), because the closing bid price of the Company's Ordinary Shares was below $1.00 per share for 30 consecutive business days. 07/16/2024
Apollomics Announces Updated Strategic Focus and Leadership Team Changes Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need 07/03/2024
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene Apollomics' partner in China, Avistone, received approval from National Medical Products Administration of China to expand the use of vebreltinib to the treatment of gliomas with PTPRZ1-MET fusion gene 04/25/2024
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancer Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancer 04/10/2024
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the full year ended December 31, 2023, and highlighted progress of its pipeline. 03/28/2024
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer FOSTER CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Matthew Plunkett, Ph.D., has been appointed as Chief Financial Officer of Apollomics. 03/04/2024
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference FOSTER CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev Redkar, Ph.D., President of Apollomics, will present virtually at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024 at 10:40 a.m. ET. 02/07/2024
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement 01/19/2024
Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference FOSTER CITY, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Guo-Liang Yu, Ph.D., Chairman and Chief Executive Officer of Apollomics, and Sanjeev Redkar, Ph.D., President of Apollomics, will participate in a Fireside Chat at the B. Riley Securities 2024 Virtual Oncology Conference on Thursday, January 18, 2024 at 11:00 a.m. ET. 01/17/2024
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia FOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced the completion of enrollment in its Phase 3 bridging study evaluating uproleselan (APL-106), an investigational, first-in-class E-selectin antagonist, added to a standard chemotherapy regimen for the treatment of adults with relapsed or refractory acute myeloid leukemia (relapsed/refractory AML). 01/03/2024
Apollomics to Present at the 2024 Biotech Showcase FOSTER CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that Sanjeev Redkar, Ph.D., Co-Founder and President, will present at the 2024 Biotech Showcase on Monday, January 8, 2024 at 10:30 a.m. PT at the Hilton San Francisco Union Square in San Francisco, Calif. 01/02/2024
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference FOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that Guo-Liang Yu, Ph.D., Co-Founder and Chief Executive Officer of Apollomics and Sanjeev Redkar, Ph.D., Co-Founder and President, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference on Wednesday, December 6, 2023 at 11:30 a.m. ET. 11/29/2023
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC) FOSTER CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced a poster presentation of clinical results for vebreltinib in the treatment of NSCLC with MET exon 14 skipping mutation with or without concurrent MET amplification at the 2023 IASLC North America Conference on Lung Cancer (NACLC), being held on December 1 through 3, 2023 in Chicago, Illinois. 11/28/2023
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer Apollomics' partner, Avistone Biotechnology, received approval from Chinese National Medical Products Administration (NMPA) to commercialize vebreltinib (APL-101) in China Compelling clinical data serving as basis of this approval supports continued development of vebreltinib for the rest of world FOSTER CITY, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that its partner in China, Avistone Biotechnology Co. Ltd. 11/16/2023
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation FOSTER CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced the addition of two new cohorts in its ongoing global multi-cohort Phase 2 SPARTA study (NCT03175224), which is evaluating vebreltinib (APL-101) in patients with non-small cell lung cancer (NSCLC) and other solid tumors (i.e., brain, esophageal, colon, pancreatic cancer) with MET dysregulations, including exon14 skipping mutation, c-MET amplification and MET fusion. 10/31/2023
Why Is Apollomics (APLM) Stock Up 113% Today? Apollomics (NASDAQ: APLM ) stock is rising higher on Friday as the shares bounce back on recent study results. Those study results cover the “efficacy response of a patient treated with vebreltinib for GBM with PTPRZ-MET fusion. 10/27/2023
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion FOSTER CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced a report by the Veneto Institute of Oncology on the efficacy response of a patient treated with vebreltinib for GBM with PTPRZ-MET fusion, at the European Society of Medical Oncology Congress (ESMO) 2023, held in Madrid, Spain from October 20-24, 2023. 10/26/2023
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75% FOSTER CITY, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European Society of Medical Oncology Congress (ESMO) 2023, being held in Madrid, Spain from October 20-24, 2023. 10/23/2023
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023 FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that two abstracts detailing vebreltinib data were made available as part of the European Society of Medical Oncology Congress (ESMO) 2023 being held in Madrid, Spain from October 20-24, 2023. 10/16/2023
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 09/28/2023
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference FOSTER CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that Sanjeev Redkar, Ph.D., Co-Founder, Executive Director and President, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13, 2023 at 10:30 a.m. ET at the Lotte New York Palace in New York, NY. 09/06/2023
Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline Apollomics is a small company with a pipeline of c-Met targeting small molecule TKIs for various cancers. Their lead candidate, Vebreltinib, is in phase 2 trials for NSCLC, GBM, and other solid tumors. They also have a second asset, APL-106, which is a specific E-Selectin antagonist being explored as a therapeutic target in certain types of cancer metastasis. 08/29/2023
The 7 Most Promising Penny Stocks to Buy in June Some of the most promising penny stocks are up-and-coming and just just getting started. The world of penny stocks is all about speculating which young firms have the potential to become the next big companies. 06/07/2023
Why Shares of Apollomics Are Up Friday Apollomics focuses on therapies for hard-to-treat cancers. The company has nine therapies, with six in clinical trials. 06/02/2023
Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM) The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 04/26/2023

Unlock

APLM Ratings Summary

APLM Quant Ranking

Is Apollomics, Inc. (APLM) a buy, sell, or hold?

What is Apollomics, Inc.'s stock price?

Is Apollomics, Inc. (APLM) overvalued or undervalued?

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference

Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia

Apollomics to Present at the 2024 Biotech Showcase

Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)